Home › Funds › Cormorant Asset Management, LP › GPCR
Cormorant Asset Management, LP position in GPCR
STRUCTURE THERAPEUTICS INC · Health Care
Cormorant Asset Management, LP reported holding 75,000 shares of GPCR (STRUCTURE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$4.0M, representing 0.21% of its reported portfolio and ranking #42 among its reported holdings. Cormorant Asset Management, LP has disclosed GPCR holdings in 3 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Cormorant Asset Management, LP's GPCR position evolved
Cormorant Asset Management, LP first disclosed a stake in GPCR in Q3 2023 at 1,056,373 shares (US$53.3M). Across 3 filings, Cormorant Asset Management, LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 75,000 shares valued at US$4.0M — a reduction of -100,000 shares quarter over quarter.. Notable position changes include a 57% trim in Q2 2026 (shares fell 42% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.06M | $53.26M | New |
| Q1 2026 | 175.00K | $8.44M | New |
| Q2 2026 | 75.00K | $4.03M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GPCR and 13F data
GPCR (STRUCTURE THERAPEUTICS INC) is a Health Care company. 33 other funds we track also report a position in GPCR — the largest reported positions include Avoro Capital Advisors LLC (US$351.8M), Deep Track Capital, LP (US$254.4M), BVF INC/IL (US$180.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GPCR
- Avoro Capital Advisors LLC 6.56M sh · $351.84M · Q2 2026
- Deep Track Capital, LP 4.74M sh · $254.40M · Q2 2026
- BVF INC/IL 3.37M sh · $180.70M · Q2 2026
- ORBIMED ADVISORS LLC 2.21M sh · $118.58M · Q2 2026
- RTW INVESTMENTS, LP 1.61M sh · $86.27M · Q2 2026
- BAKER BROS. ADVISORS LP 1.43M sh · $76.88M · Q2 2026
- Casdin Capital 1.18M sh · $63.06M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.09M sh · $58.29M · Q2 2026
- Siren, L.L.C. 872.97K sh · $46.85M · Q2 2026
- PACIFIC HEIGHTS ASSET MANAGEMENT LLC 800.00K sh · $42.94M · Q2 2026
- Rock Springs Capital Management LP 640.32K sh · $34.37M · Q2 2026
- Logos Global Management LP 500.00K sh · $26.84M · Q2 2026
More on Cormorant Asset Management, LP
FAQ
How long has Cormorant Asset Management, LP held GPCR?
Cormorant Asset Management, LP has disclosed GPCR holdings in 3 of the last 12 reported quarters, going back to Q3 2023.
What is Cormorant Asset Management, LP's current position in GPCR?
As of Q2 2026, Cormorant Asset Management, LP holds 75.00K shares of GPCR (STRUCTURE THERAPEUTICS INC), valued at $4.03M, representing 0.21% of its reported portfolio and ranking #42.
Has Cormorant Asset Management, LP been buying or selling GPCR?
In the latest 13F filing (Q2 2026), Cormorant Asset Management, LP reduced its position in GPCR.
Which other funds hold GPCR?
Other major institutional holders of GPCR include Avoro Capital Advisors LLC, Deep Track Capital, LP, BVF INC/IL, among 33 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.